Zentalis
Zentalis :
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
1359 Broadway
Suite 1710
New York, NY 12065
United States
Suite 1710
New York, NY 12065
United States
More info:
My account:
Company Participants at Zentalis R&D Day
- Anthony Sun, CEO
Lead Programs
ZN-c3: WEE1i
Potentially first- and best-in class oral inhibitor
| Indication | Phase |
|---|---|
| Monotherapy & Combination studies (Multiple) | 1/2 |
ZN-d5: BCL-2
Oral selective inhibitor of B-cell lymphoma 2 (BCL-2)
| Indication | Phase |
|---|---|
| Hematologic Malignancies and related disorders | 1/2 |
BCL-xL Degrader
Solid Tumors and Hematologic Malignancies
| Indication | Phase |
|---|---|
| Solid Tumors and Heme Malignancies | Pre-clinical |
Top 10 Holders of Zentalis Pharmaceuticals, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Matrix Capital Management Co. LP | 19.80 | 13,959,973 | 280.04 | 13F | 6/30/23 |
| Fidelity Management & Research Co. LLC | 12.58 | 8,869,493 | 177.92 | 13F | 6/30/23 |
| Eventide Asset Management LLC | 9.75 | 6,877,803 | 137.97 | 13F | 6/30/23 |
| Vanguard Group, Inc. (Subfiler) | 6.78 | 4,782,483 | 95.94 | 13F | 6/30/23 |
| State Street Corp. | 4.47 | 3,152,914 | 63.25 | 13F | 6/30/23 |
| Capital Research & Management Co. (International Investors) | 4.44 | 3,127,758 | 62.74 | 13F | 6/30/23 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 3.76 | 2,648,978 | 53.14 | 13F | 6/30/23 |
| Avidity Partners Management LP | 3.31 | 2,334,000 | 46.82 | 13F | 6/30/23 |
| T. Rowe Price Associates, Inc. (Investment Management) | 3.30 | 2,323,771 | 46.61 | Funds | 8/31/23 |
| BlackRock Fund Advisors | 3.07 | 2,162,328 | 43.38 | 13F | 6/30/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.